Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mack

Showing results (351-360 of 432) with videos related to

Pageof 44
Sort By:
Journal of Medicinal Chemistry|November 7, 2000
(-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptorG Mullen, J Napier, M Balestra, et al.
Redox Biology|May 18, 2026
Serum thiol redox-related alterations in asymptomatic first-degree relatives are associated with future Crohn's diseaseKaiwen Mu, Mingyue Xue, Hien Q Huynh, et al.
The Journal of Allergy and Clinical Immunology|August 16, 2017
Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itchJialie Luo, Jing Feng, Guang Yu, et al.
Inflammatory Bowel Diseases|February 11, 2026
Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohortAmanda Ricciuto, Andrei L Turinsky, Anne M Griffiths, et al.
Inflammatory Bowel Diseases|May 3, 2014
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's diseasePhillip Minar, Yael Haberman, Ingrid Jurickova, et al.
Antimicrobial Agents and Chemotherapy|October 30, 2024
ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibutenMichael R Jacobs, Caryn E Good, Ayman M Abdelhamed, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.
Inflammatory Bowel Diseases|May 22, 2019
Characterization of Stool Virome in Children Newly Diagnosed With Moderate to Severe Ulcerative ColitisRafal Tokarz, Jeffrey S Hyams, David R Mack, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2020
A comprehensive and contemporary "snapshot" of β-lactamases in carbapenem resistant Acinetobacter baumanniiAndrea M Hujer, Kristine M Hujer, David A Leonard, et al.
Inflammatory Bowel Diseases|July 2, 2014
Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's diseaseWhitney Sunseri, Jeffrey S Hyams, Trudy Lerer, et al.
Pageof 44

Showing results (351-360 of 432) with videos related to

Sort By:
Pageof 44
Journal of Medicinal Chemistry|November 7, 2000
(-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptorG Mullen, J Napier, M Balestra, et al.
Redox Biology|May 18, 2026
Serum thiol redox-related alterations in asymptomatic first-degree relatives are associated with future Crohn's diseaseKaiwen Mu, Mingyue Xue, Hien Q Huynh, et al.
The Journal of Allergy and Clinical Immunology|August 16, 2017
Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itchJialie Luo, Jing Feng, Guang Yu, et al.
Inflammatory Bowel Diseases|February 11, 2026
Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohortAmanda Ricciuto, Andrei L Turinsky, Anne M Griffiths, et al.
Inflammatory Bowel Diseases|May 3, 2014
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's diseasePhillip Minar, Yael Haberman, Ingrid Jurickova, et al.
Antimicrobial Agents and Chemotherapy|October 30, 2024
ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibutenMichael R Jacobs, Caryn E Good, Ayman M Abdelhamed, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.
Inflammatory Bowel Diseases|May 22, 2019
Characterization of Stool Virome in Children Newly Diagnosed With Moderate to Severe Ulcerative ColitisRafal Tokarz, Jeffrey S Hyams, David R Mack, et al.
Diagnostic Microbiology and Infectious Disease|November 28, 2020
A comprehensive and contemporary "snapshot" of β-lactamases in carbapenem resistant Acinetobacter baumanniiAndrea M Hujer, Kristine M Hujer, David A Leonard, et al.
Inflammatory Bowel Diseases|July 2, 2014
Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's diseaseWhitney Sunseri, Jeffrey S Hyams, Trudy Lerer, et al.
Pageof 44